

Introduction

Technological advances, combined with improved understanding of the genetic basis of cancer, have revolutionized the way we treat cancer. Today, clinicians are increasingly utilizing information on genetic alterations to guide and optimize treatment options for cancer patients, leading to increased survival and better quality of life.

BGI's SENTIS™ Targeted Therapy Genetic Test provides clinicians with a comprehensive and accurate Next Generation Sequencing (NGS) based test solution for the identification of clinically actionable mutations in cancer. Testing can be conducted from either tissue or liquid biopsy samples.

The Power of Knowing

BGI SENTIS™ Targeted Therapy (Tissue/ctDNA)

Advantages

Comprehensive

Whole exon coverage of 206 genes with therapeutic relevance, supporting most common types of genomic alterations including base substitutions, InDel, CNV and fusion

Provides interpretation on 95 targeted therapies, including 56 approved by authorities (FDA, EMA, PMDA or CFDA), and 39 agents in active clinical trials

Flexible

Accepts various sample types:

- BGI SENTIS™ Targeted Therapy (Tissue): fresh tissue, biopsy, ascites/pleural effusion, FFPE, or DNA
- BGI SENTIS™ Targeted Therapy (ctDNA): peripheral blood or DNA

High Performance

Sensitivity/Specificity >97%*

Liquid biopsy version allows genetic profiling in situations where tissue is not available or continuous monitoring of tumor molecular profile is required

*: See technical information for details.

The Power of Knowing

BGI SENTIS™ Targeted Therapy (Tissue/ctDNA)

Technical Information

	TYPICAL MEDIAN DEPTH OF COVERAGE	SENSITIVITY	SPECIFICITY
BGI SENTIS™ Targeted Therapy (Tissue)	200x	>99% MAF ≥ 3%	>98% MAF ≥ 3%
BGI SENTIS™ Targeted Therapy (ctDNA)	1000x	>97% MAF ≥ 1%	>100% MAF ≥ 1%

Sample Requirements

BGI SENTIS™ Targeted Therapy (Tissue)

- >60mg tissue or 15 FFPE 10mm*10mm (5-10µm) sections or ≥3 samplings of biopsy or ≥100mL ascites/pleural effusion or ≥1µg good quality, tumor DNA;

- 5mL of peripheral blood

BGI SENTIS™ Targeted Therapy (ctDNA)

- ≥10mL of peripheral blood (separated plasma and formed elements) or ≥8mL of peripheral blood collected in Streck Cell-Free DNA BCT® tube


Ordering Information

ITEM	CATALOG NO.
BGI SENTIS™ Targeted Therapy (Tissue)	DX1346
BGI SENTIS™ Targeted Therapy (ctDNA)	DX1460

Turnaround time

10 working days (from sample arriving at BGI lab to report)

Workflow



Contact your local BGI representative for more information or email info@bgi-international.com.

More information can also be found on our website.

www.bgi.com/global/

Copyright© 2017 BGI. Copyright© 2017 BGI. The BGI logo and SENTIS logo are trademarks of BGI. All rights reserved.

Published June 2017, version 1.0

For Research Use Only. Not for use in diagnostic procedures.

Testing services not currently available in the United States of America. Please contact a representative for regional availability.

